Leqembi
Drug
Eisai Inc.
Total Payments
$85.9M
Transactions
41,346
Doctors
11,872
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $25.4M | 29,031 | 10,241 |
| 2023 | $60.5M | 12,315 | 4,738 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $80.5M | 3,292 | 93.7% |
| Consulting Fee | $1.7M | 555 | 2.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1.7M | 1,272 | 1.9% |
| Food and Beverage | $1.0M | 34,745 | 1.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $590,556 | 222 | 0.7% |
| Travel and Lodging | $315,198 | 1,059 | 0.4% |
| Grant | $30,500 | 3 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $21,050 | 11 | 0.0% |
| Education | $5,502 | 187 | 0.0% |
Payments by Type
Research
$80.5M
3,292 transactions
General
$5.4M
38,054 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | Eisai Inc. | $52.9M | 0 |
| AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | Eisai Inc. | $22.7M | 0 |
| A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | Eisai Inc. | $4.5M | 0 |
| A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | EISAI INC. | $339,696 | 0 |
| AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | EISAI INC. | $120.00 | 0 |
Top Doctors Receiving Payments for Leqembi
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Falls Church, VA | $80.5M | 3,340 |
| , MD | Psychiatry | Philadelphia, PA | $195,538 | 14 |
| , M.D | Behavioral Neurology & Neuropsychiatry | Travis, TX | $145,551 | 119 |
| , M.D | Neurology | Harris, TX | $132,794 | 135 |
| , MD | Neurology | Forrest, MS | $123,253 | 128 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Chatham, GA | $115,162 | 98 |
| , M.D | Behavioral Neurology & Neuropsychiatry | St Joseph, IN | $112,416 | 120 |
| , M.D | Behavioral Neurology & Neuropsychiatry | Montgomery, PA | $110,850 | 105 |
| , MD | Neurology | San Francisco, CA | $106,419 | 95 |
| , M.D, M.P.H | Neurology | Denver, CO | $94,674 | 108 |
| Julie Schwartzbard | — | Miami-Dade, FL | $94,550 | 63 |
| , MD | Spinal Cord Injury Medicine | Baltimore, MD | $87,359 | 99 |
| , MD | Neurology | Miami-Dade, FL | $71,251 | 100 |
| , MD | Neurology | Orange, FL | $70,681 | 89 |
| , M.D | Neurology | Denver, CO | $61,680 | 67 |
| , M.D | Neurology | Los Angeles, CA | $61,494 | 89 |
| , MD | Neurology | Ramsey, MN | $61,453 | 64 |
| , M.D., PH.D | Neurology | New Haven, CT | $61,022 | 66 |
| , M.D | Neurology | Muscogee, GA | $60,082 | 72 |
| , MD | Neurology | Clark, NV | $58,788 | 42 |
| , DO | Neurology | Maricopa, AZ | $56,022 | 117 |
| , DO | Neurology | Shiawassee, MI | $51,482 | 87 |
| , M.D | Psychiatry | Dallas, TX | $49,400 | 83 |
| , MD | Neurology | Polk, MO | $49,036 | 60 |
| , MD | Family Medicine | Polk, IA | $46,447 | 57 |
Ad
Manufacturing Companies
- Eisai Inc. $85.5M
- EISAI INC. $340,109
- Eisai Co., Ltd. $4,904
Product Information
- Type Drug
- Total Payments $85.9M
- Total Doctors 11,872
- Transactions 41,346
About Leqembi
Leqembi is a drug associated with $85.9M in payments to 11,872 healthcare providers, recorded across 41,346 transactions in the CMS Open Payments database. The primary manufacturer is Eisai Inc..
Payment data is available from 2023 to 2024. In 2024, $25.4M was paid across 29,031 transactions to 10,241 doctors.
The most common payment nature for Leqembi is "Unspecified" ($80.5M, 93.7% of total).
Leqembi is associated with 5 research studies, including "A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease" ($52.9M).